NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

Download real time

1693.00 48.00 (2.92%)

Near 52W High of ₹1740.00

712.3K NSE+BSE Volume

NSE 09 Oct, 2026 3:31 PM (IST)

98,329.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Search Inside the pdf :

Aurobindo Pharma Ltd.

07 Aug 2026

1693.00

2.92%

Outlook

Accumulate: Aurobindo Pharma Ltd.

Target

Deven Choksey

Aurobindo Pharma is well positioned to deliver sustainable double-digit growth, supported by healthy momentum across its US, Europe, India, and Growth Markets businesses, along with a steady cadence of complex product launches.

Aurobindo Pharma Ltd.'s price crossed above 50Day SMA today

Aurobindo Pharma Ltd.

06 Aug 2026

1693.00

2.92%

Operational delivery remains on track

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered in-line revenue in 1QFY27. It delivered better-than-expected EBITDA/PAT (6%/8% beat) for the quarter.

Promoters unpledged 9.90% of shares in last quarter. Total pledge stands at 13.75% of promoter holdings

Aurobindo Pharma Ltd.

01 Jun 2026

1693.00

2.92%

Regulatory Overhang Could Delay US Growth Aspirations

Hold: Aurobindo Pharma Ltd.

Target

Deven Choksey

Eugia's injectable facilities creating uncertainty around the pace of US growth and the achievement of its USD 2 billion revenue aspiration.

Promoters unpledged 9.90% of shares in last quarter. Total pledge stands at 13.75% of promoter holdings

Aurobindo Pharma Ltd.

25 May 2026

1693.00

2.92%

Aurobindo Pharma (ARBP IN) Q4FY26 Result Update Muted US sales Downgrade to HOLD'

Hold: Aurobindo Pharma Ltd.

Recommendation Target

Prabhudas Lilladhar

Revenues below est, weak US business: Overall Revenue came in at INR 88.5bn, up 5.6% YoY, (we est INR 87.9bn). US revenues stood at USD 387mn, down 8% QoQ and 18% YoY (we est USD 426mn). Mgmt cited ex gRevlimid improvement in base business was visible YoY. EU sales up 30% YoY to INR 28bn, beat our est. ARV...

Aurobindo Pharma has gained 58.11% in the last 1 Year

Aurobindo Pharma Ltd.

22 May 2026

1693.00

2.92%

Aurobindo Pharma (BUY): In-line estimates; growth drivers intact

Buy: Aurobindo Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were reported 1.4%/-0.3%/5.6% above our estimates. EBITDA margin came 34 bps lower than our estimates

Aurobindo Pharma Ltd.'s price crossed above 30Day SMA today

Aurobindo Pharma Ltd.

01 Apr 2026

1693.00

2.92%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

ARBP is accelerating its growth momentum by leveraging its extensive generic portfolio and expanding into high-margin specialty and injectable segments. The company is focusing on the US market with a mix of complex generics and unique products, which is expected to result in a more balanced revenue mix. Additionally, the development of injectable and specialty products is expected to unlock new growth opportunities as they enter the commercialisation stage. The company's...

Aurobindo Pharma has gained 58.11% in the last 1 Year

Aurobindo Pharma Ltd.

23 Mar 2026

1693.00

2.92%

Backward & forward integration unlocking PenG value chain

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Under the Production-Linked Incentive (PLI) scheme, ARBP constructed the PENG and 6-APA plants within a record three-year period and ramped up production following the start of the PEN-G plant in Jul’25.

Aurobindo Pharma has gained 58.11% in the last 1 Year

Aurobindo Pharma Ltd.

15 Feb 2026

1693.00

2.92%

Aurobindo Pharma Ltd.

Buy: Aurobindo Pharma Ltd.

Target

ICICI Direct

The performance was more or less in sync with the overall FY26 management guidance with flattish US growth (wanning gRevlimid traction and pending approvals from Eugia III), overall single-digit growth, and EBITDA margins around ~21% (came in slightly lower though). European growth has been consistently strong over the last few quarters. Going forward, while sustainability of the EBITDA margins will be the key monitorable as the company plans to expand the R&D bandwidth and diversify into more complex models such as biosimilars, the GPMs are...